Species | Potential target | Raw | Global | Species |
---|---|---|---|---|
Mycobacterium tuberculosis | Probable 3-hydroxyacyl-thioester dehydratase HtdY | 0.004 | 0.0355 | 0.1391 |
Mycobacterium ulcerans | hypothetical protein | 0.004 | 0.0355 | 0.1391 |
Chlamydia trachomatis | holo [acyl-carrier protein] synthase | 0.0164 | 0.2552 | 0.5 |
Leishmania major | phosphopantetheinyl transferase-like protein | 0.0164 | 0.2552 | 0.5 |
Toxoplasma gondii | sterol carrier protein-2 HAD-2SCP-2 | 0.0036 | 0.0281 | 0.0841 |
Mycobacterium leprae | conserved hypothetical protein | 0.0164 | 0.2552 | 0.5 |
Loa Loa (eye worm) | hypothetical protein | 0.004 | 0.0355 | 0.0355 |
Wolbachia endosymbiont of Brugia malayi | 4'-phosphopantetheinyl transferase | 0.0164 | 0.2552 | 0.5 |
Trypanosoma brucei | hypothetical protein, conserved | 0.0164 | 0.2552 | 0.5 |
Entamoeba histolytica | hypothetical protein | 0.0164 | 0.2552 | 0.5 |
Mycobacterium ulcerans | dehydratase | 0.004 | 0.0355 | 0.1391 |
Treponema pallidum | 4'-phosphopantetheinyl transferase | 0.0164 | 0.2552 | 0.5 |
Mycobacterium ulcerans | 4'-phosphopantetheinyl transferase | 0.0164 | 0.2552 | 1 |
Mycobacterium tuberculosis | holo-[acyl-carrier protein] synthase AcpS (holo-ACP synthase) (CoA:APO-[ACP]pantetheinephosphotransferase) (CoA:APO-[acyl-carrie | 0.0164 | 0.2552 | 1 |
Mycobacterium ulcerans | phosphopantetheinyl transferase, PptII | 0.0164 | 0.2552 | 1 |
Plasmodium falciparum | holo-[acyl-carrier-protein] synthase, putative | 0.0164 | 0.2552 | 0.5 |
Plasmodium vivax | holo-[acyl-carrier-protein] synthase, putative | 0.0164 | 0.2552 | 0.5 |
Brugia malayi | maoC like domain containing protein | 0.004 | 0.0355 | 0.0355 |
Mycobacterium tuberculosis | Probable dehydrogenase. Possible 2-enoyl acyl-CoA hydratase. | 0.004 | 0.0355 | 0.1391 |
Toxoplasma gondii | 4'-phosphopantetheinyl transferase domain-containing protein | 0.0164 | 0.2552 | 1 |
Toxoplasma gondii | 4'-phosphopantetheinyl transferase superfamily protein | 0.0164 | 0.2552 | 1 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.